ATG13 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma cells carrying targeted disruptions in the ATG13 gene. This polyclonal knockout model avoids clonal artifacts and provides a physiologically diverse loss-of-function system for autophagy research.
The parental A-549 cell line is an alveolar basal epithelial adenocarcinoma with a KRAS G12S mutation and wild-type TP53, exhibiting epithelial morphology. Widely used to model lung cancer and respiratory epithelium, its oncogenic KRAS background creates a dependency on autophagy for metabolic adaptation, making it an ideal host for studying ATG13 function.
ATG13 is a core scaffold of the ULK1 kinase complex, bridging ULK1/ULK2, FIP200 (RB1CC1), and ATG101 to initiate autophagy. The complex is regulated by nutrient-sensing kinases: mTORC1 phosphorylates ATG13 to inhibit activity under fed conditions, while AMPK phosphorylates and activates ULK1 upon starvation, promoting complex assembly. Active ULK1 subsequently drives Beclin-1?CPI3K class III complex engagement, LC3 lipidation, ATG5?CATG12 conjugation, and autophagosome nucleation. Hence, ATG13 knockout blocks these downstream events, impairing autophagic degradation.
In A-549 cells, loss of ATG13 cripples autophagic flux and sensitizes cells to nutrient deprivation, revealing a key survival role for autophagy downstream of mutant KRAS. This model allows dissection of ATG13-dependent pro-survival signaling, investigation of synthetic lethalities, and exploration of how autophagy intersects with stress adaptation and drug response in lung adenocarcinoma.
Applications include western blotting for LC3-II and p62, autophagic flux assays, immunofluorescence for LC3 puncta, viability tests under starvation or drug challenge, co-immunoprecipitation of ULK1 components, mTORC1 activity readouts, and RT-qPCR for autophagy gene expression. The cells support studies in autophagy-regulated lung cancer biology, drug resistance, mTOR pathway signaling, and screening of autophagy modulators. For additional technical details, contact Ascent Research.
